Categories Earnings, Health Care

Exact Sciences Corp. (EXAS): Q4 2019 Earnings Snapshot

— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.

— Total revenues were $295.6 million, vs. $283 million expected.

— Screening revenues increased 60% to $229.4 million.

— Cologuard test volume rose 63% to 477,000.

— Average Cologuard recognized revenue per test was $481.

— Average Cologuard cost per test was $123.

— Precision Oncology proforma revenue increased 14% to $119.1 million.

— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.

— FY2020 Screening revenue is expected to be $1.125-1.15 billion.

— FY2020 Precision Oncology revenue is expected to be $485-495 million.

— EXAS shares gained 1.2% immediately following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Here’s a look at Dollar Tree’s (DLTR) expectations for the remainder of the year

Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings

Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop

Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported

Is Zoom Video Communications (ZM) a good investment after Q3 earnings?

Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top